Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR2 | Q92731 | 2/20 | 0.46 |
| ▸ | ESR1 | P03372 | 1/20 | 0.46 |
| ▸ | NOX1 | Q9Y5S8 | 1/20 | 0.41 |
| ▸ | PPARD | Q03181 | 6/20 | 0.39 |
| ▸ | MAPT | P10636 | 5/20 | 0.39 |
| ▸ | TP53 | P04637 | 2/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.38 |
| ▸ | MEN1 | O00255 | 2/20 | 0.38 |
| ▸ | NPC1 | O15118 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | POLB | P06746 | 1/20 | 0.37 |
| ▸ | ATM | Q13315 | 1/20 | 0.37 |
| ▸ | APP | P05067 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.36 |
| ▸ | LTA4H | P09960 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6539945 | 0.87 | PTGS2 (0.39) | PPARDMAPTKMT2AMEN1KDM4E | |
| SCHEMBL6539116 | 0.86 | ESR2 (0.43) | ESR2ESR1NOX1PPARDMAPT | |
| SCHEMBL6539632 | 0.84 | ESR2 (0.45) | ESR2ESR1NOX1PPARDMAPT | |
| SCHEMBL12286391 | 0.84 | PPARD (0.39) | ESR2ESR1PPARDMAPTNPC1 | |
| SCHEMBL6208355 | 0.82 | ESR2 (0.49) | ESR2ESR1NOX1PPARDMAPT | |
| SCHEMBL6539838 | 0.81 | PTGS2 (0.35) | PPARDMAPTKMT2AMEN1KDM4E | |
| SCHEMBL6230071 | 0.81 | ESR2 (0.47) | ESR2ESR1NOX1PPARDMAPT | |
| SCHEMBL6539500 | 0.81 | ESR2 (0.47) | ESR2ESR1NOX1PPARDMAPT | |
| SCHEMBL12462259 | 0.81 | PPARD (0.41) | PPARDMAPTTP53NPC1KDM4E | |
| SCHEMBL13352333 | 0.81 | PPARD (0.39) | PPARDMAPTKMT2ANPC1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1583749-A1 | OXAZOLE DERIVATIVES AS INHIBITORS OF CYCLOOXYGENASE | Astellas Pharma Inc. (JP) | 2005-10-12 | — | — | EP | disclosed |
| US-20040157891-A1 | Inhibitor of cox | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2004-08-12 | — | — | US | disclosed |
| WO-2004065374-A1 | OXAZOLE DERIVATIVES AS INHIBITORS OF CYCLOOXYGENASE | ASTELLAS PHARMA INC. (JP) | 2004-08-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040157891-A1 | Inhibitor of cox | PTGS1, PTGS2, PTGES2 | ESR2 667/4885ESR1 2518/4885NOX1 295/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.